These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
467 related articles for article (PubMed ID: 27064194)
1. Updated trends in US brand-name and generic drug competition. Grabowski H; Long G; Mortimer R; Boyo A J Med Econ; 2016 Sep; 19(9):836-44. PubMed ID: 27064194 [TBL] [Abstract][Full Text] [Related]
2. Recent trends in brand-name and generic drug competition. Grabowski H; Long G; Mortimer R J Med Econ; 2014 Mar; 17(3):207-14. PubMed ID: 24320785 [TBL] [Abstract][Full Text] [Related]
3. Continuing trends in U.S. brand-name and generic drug competition. Grabowski H; Long G; Mortimer R; Bilginsoy M J Med Econ; 2021; 24(1):908-917. PubMed ID: 34253119 [TBL] [Abstract][Full Text] [Related]
4. Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases. Kerr KW; Glos LJ Pharmaceut Med; 2020 Feb; 34(1):19-29. PubMed ID: 32048213 [TBL] [Abstract][Full Text] [Related]
5. Determinants of Market Exclusivity for Prescription Drugs in the United States. Kesselheim AS; Sinha MS; Avorn J JAMA Intern Med; 2017 Nov; 177(11):1658-1664. PubMed ID: 28892528 [TBL] [Abstract][Full Text] [Related]
6. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms. Panattoni LE J Health Econ; 2011 Jan; 30(1):126-45. PubMed ID: 21074873 [TBL] [Abstract][Full Text] [Related]
7. Teva v. Eisai: what's the real "controversy"? Wang GL Food Drug Law J; 2011; 66(4):631-54, iii. PubMed ID: 24505831 [TBL] [Abstract][Full Text] [Related]
8. The timing of 30-month stay expirations and generic entry: A cohort study of first generics, 2013-2020. Kannappan S; Darrow JJ; Kesselheim AS; Beall RF Clin Transl Sci; 2021 Sep; 14(5):1917-1923. PubMed ID: 33982425 [TBL] [Abstract][Full Text] [Related]
9. Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012-2018. Rome BN; Lee CC; Kesselheim AS Clin Pharmacol Ther; 2021 Feb; 109(2):367-371. PubMed ID: 32654122 [TBL] [Abstract][Full Text] [Related]
10. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals. Hao J; Rodriguez-Monguio R; Seoane-Vazquez E PLoS One; 2015; 10(10):e0140708. PubMed ID: 26469277 [TBL] [Abstract][Full Text] [Related]
11. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration. Hong SH; Shepherd MD; Scoones D; Wan TT J Manag Care Pharm; 2005; 11(9):746-54. PubMed ID: 16300418 [TBL] [Abstract][Full Text] [Related]
12. Generic Drugs in the United States: Policies to Address Pricing and Competition. Gupta R; Shah ND; Ross JS Clin Pharmacol Ther; 2019 Feb; 105(2):329-337. PubMed ID: 30471089 [TBL] [Abstract][Full Text] [Related]
13. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act. Apel BT Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458 [TBL] [Abstract][Full Text] [Related]
14. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS. Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194 [TBL] [Abstract][Full Text] [Related]
16. Association of authorized generic marketing with prescription drug spending on antidepressants from 2000 to 2011. Cheng N; Banerjee T; Qian J; Hansen RA J Am Pharm Assoc (2003); 2017; 57(3):341-348. PubMed ID: 28400255 [TBL] [Abstract][Full Text] [Related]
17. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study. Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641 [TBL] [Abstract][Full Text] [Related]
18. Strategies That Delay Market Entry of Generic Drugs. Vokinger KN; Kesselheim AS; Avorn J; Sarpatwari A JAMA Intern Med; 2017 Nov; 177(11):1665-1669. PubMed ID: 28975217 [TBL] [Abstract][Full Text] [Related]
19. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending. Luo J; Seeger JD; Donneyong M; Gagne JJ; Avorn J; Kesselheim AS JAMA Intern Med; 2016 Sep; 176(9):1317-23. PubMed ID: 27367749 [TBL] [Abstract][Full Text] [Related]
20. Patent Challenges And Litigation On Inhalers For Asthma And COPD. Reddy S; Beall RF; Tu SS; Kesselheim AS; Feldman WB Health Aff (Millwood); 2023 Mar; 42(3):398-406. PubMed ID: 36877911 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]